Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder

26-Week prospective study

Jun Soo Kwon, Joon Hwan Jang, Do Hyung Kang, So Young Yoo, Yong Ku Kim, Seong Jin Cho, Hyun Yoon Bo, Seok Jeong Bum, Ook Lee Byung, Hyung Kim Chan, Yoon Kim Chang, Chi Un Pae, Eung Kim Chul, Hoon Kim Do, Seok Yang Dong, Duk In Jon, Jae-Jin Kim, Gong Cyn Jae, Jeong Ho Seok, Gee Kim Jeong & 14 others Jong Il Lee, Jung Seo Yi, Goo Lee Jung, Sue Hong Kyung, Min Soo Lee, Ick Lee Sang, Yeol Lee Sang, Woo Lee Sun, Tak Youn, Won Myong Bahk, Yanghyun Lee, Chul Chung Young, Chul Shin Young, Hoon Kim Young

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aims: To date there have been no reports of long-term efficacy of aripiprazole in Asian populations. The aim of the present study was therefore to investigate the long-term efficacy, safety and tolerability of aripiprazole in a large number of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder in Korea. Methods: This study was a prospective, multicenter, single-group, 26-week open study of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. A total of 300 Korean patients participated in the study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score, and secondary efficacy measures included the PANSS positive and negative subscales, Clinical Global Impression-Severity of Illness (CGI-S). Tolerability and safety were assessed by monitoring the frequency and severity of treatment-emergent adverse events, extrapyramidal symptoms (EPS), vital signs, weight, and laboratory tests. Results: Aripiprazole produced rapid and significant improvements on all efficacy measures. As evidenced by PANSS total score, PANSS positive subscales and the CGI-S scores, first-episode drug-naïve patients demonstrated significantly greater efficacy relative to patients who had previously experienced one or more episodes of relapse. Aripiprazole was associated with significant decrease of serum prolactin level. The subjects showed mild weight gain. Conclusion: Aripiprazole is an effective antipsychotic in the long-term treatment of both positive and negative symptoms. This study extends the findings of previous long-term studies, and has found that there is no significant difference with regard to ethnicity in response to aripiprazole.

Original languageEnglish
Pages (from-to)73-81
Number of pages9
JournalPsychiatry and Clinical Neurosciences
Volume63
Issue number1
DOIs
Publication statusPublished - 2009 Feb 1

Fingerprint

Psychotic Disorders
Schizophrenia
Prospective Studies
Safety
Vital Signs
Korea
Prolactin
Antipsychotic Agents
Weight Gain
Aripiprazole
Weights and Measures
Recurrence
Therapeutics
Serum
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Kwon, Jun Soo ; Jang, Joon Hwan ; Kang, Do Hyung ; Yoo, So Young ; Kim, Yong Ku ; Cho, Seong Jin ; Bo, Hyun Yoon ; Bum, Seok Jeong ; Byung, Ook Lee ; Chan, Hyung Kim ; Chang, Yoon Kim ; Pae, Chi Un ; Chul, Eung Kim ; Do, Hoon Kim ; Dong, Seok Yang ; Jon, Duk In ; Kim, Jae-Jin ; Jae, Gong Cyn ; Seok, Jeong Ho ; Jeong, Gee Kim ; Lee, Jong Il ; Yi, Jung Seo ; Jung, Goo Lee ; Kyung, Sue Hong ; Lee, Min Soo ; Sang, Ick Lee ; Sang, Yeol Lee ; Sun, Woo Lee ; Youn, Tak ; Bahk, Won Myong ; Lee, Yanghyun ; Young, Chul Chung ; Young, Chul Shin ; Young, Hoon Kim. / Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder : 26-Week prospective study. In: Psychiatry and Clinical Neurosciences. 2009 ; Vol. 63, No. 1. pp. 73-81.
@article{50f34c5eedda472e92a2163bb5993b39,
title = "Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-Week prospective study",
abstract = "Aims: To date there have been no reports of long-term efficacy of aripiprazole in Asian populations. The aim of the present study was therefore to investigate the long-term efficacy, safety and tolerability of aripiprazole in a large number of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder in Korea. Methods: This study was a prospective, multicenter, single-group, 26-week open study of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. A total of 300 Korean patients participated in the study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score, and secondary efficacy measures included the PANSS positive and negative subscales, Clinical Global Impression-Severity of Illness (CGI-S). Tolerability and safety were assessed by monitoring the frequency and severity of treatment-emergent adverse events, extrapyramidal symptoms (EPS), vital signs, weight, and laboratory tests. Results: Aripiprazole produced rapid and significant improvements on all efficacy measures. As evidenced by PANSS total score, PANSS positive subscales and the CGI-S scores, first-episode drug-na{\"i}ve patients demonstrated significantly greater efficacy relative to patients who had previously experienced one or more episodes of relapse. Aripiprazole was associated with significant decrease of serum prolactin level. The subjects showed mild weight gain. Conclusion: Aripiprazole is an effective antipsychotic in the long-term treatment of both positive and negative symptoms. This study extends the findings of previous long-term studies, and has found that there is no significant difference with regard to ethnicity in response to aripiprazole.",
author = "Kwon, {Jun Soo} and Jang, {Joon Hwan} and Kang, {Do Hyung} and Yoo, {So Young} and Kim, {Yong Ku} and Cho, {Seong Jin} and Bo, {Hyun Yoon} and Bum, {Seok Jeong} and Byung, {Ook Lee} and Chan, {Hyung Kim} and Chang, {Yoon Kim} and Pae, {Chi Un} and Chul, {Eung Kim} and Do, {Hoon Kim} and Dong, {Seok Yang} and Jon, {Duk In} and Jae-Jin Kim and Jae, {Gong Cyn} and Seok, {Jeong Ho} and Jeong, {Gee Kim} and Lee, {Jong Il} and Yi, {Jung Seo} and Jung, {Goo Lee} and Kyung, {Sue Hong} and Lee, {Min Soo} and Sang, {Ick Lee} and Sang, {Yeol Lee} and Sun, {Woo Lee} and Tak Youn and Bahk, {Won Myong} and Yanghyun Lee and Young, {Chul Chung} and Young, {Chul Shin} and Young, {Hoon Kim}",
year = "2009",
month = "2",
day = "1",
doi = "10.1111/j.1440-1819.2008.01907.x",
language = "English",
volume = "63",
pages = "73--81",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "1",

}

Kwon, JS, Jang, JH, Kang, DH, Yoo, SY, Kim, YK, Cho, SJ, Bo, HY, Bum, SJ, Byung, OL, Chan, HK, Chang, YK, Pae, CU, Chul, EK, Do, HK, Dong, SY, Jon, DI, Kim, J-J, Jae, GC, Seok, JH, Jeong, GK, Lee, JI, Yi, JS, Jung, GL, Kyung, SH, Lee, MS, Sang, IL, Sang, YL, Sun, WL, Youn, T, Bahk, WM, Lee, Y, Young, CC, Young, CS & Young, HK 2009, 'Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-Week prospective study', Psychiatry and Clinical Neurosciences, vol. 63, no. 1, pp. 73-81. https://doi.org/10.1111/j.1440-1819.2008.01907.x

Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder : 26-Week prospective study. / Kwon, Jun Soo; Jang, Joon Hwan; Kang, Do Hyung; Yoo, So Young; Kim, Yong Ku; Cho, Seong Jin; Bo, Hyun Yoon; Bum, Seok Jeong; Byung, Ook Lee; Chan, Hyung Kim; Chang, Yoon Kim; Pae, Chi Un; Chul, Eung Kim; Do, Hoon Kim; Dong, Seok Yang; Jon, Duk In; Kim, Jae-Jin; Jae, Gong Cyn; Seok, Jeong Ho; Jeong, Gee Kim; Lee, Jong Il; Yi, Jung Seo; Jung, Goo Lee; Kyung, Sue Hong; Lee, Min Soo; Sang, Ick Lee; Sang, Yeol Lee; Sun, Woo Lee; Youn, Tak; Bahk, Won Myong; Lee, Yanghyun; Young, Chul Chung; Young, Chul Shin; Young, Hoon Kim.

In: Psychiatry and Clinical Neurosciences, Vol. 63, No. 1, 01.02.2009, p. 73-81.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder

T2 - 26-Week prospective study

AU - Kwon, Jun Soo

AU - Jang, Joon Hwan

AU - Kang, Do Hyung

AU - Yoo, So Young

AU - Kim, Yong Ku

AU - Cho, Seong Jin

AU - Bo, Hyun Yoon

AU - Bum, Seok Jeong

AU - Byung, Ook Lee

AU - Chan, Hyung Kim

AU - Chang, Yoon Kim

AU - Pae, Chi Un

AU - Chul, Eung Kim

AU - Do, Hoon Kim

AU - Dong, Seok Yang

AU - Jon, Duk In

AU - Kim, Jae-Jin

AU - Jae, Gong Cyn

AU - Seok, Jeong Ho

AU - Jeong, Gee Kim

AU - Lee, Jong Il

AU - Yi, Jung Seo

AU - Jung, Goo Lee

AU - Kyung, Sue Hong

AU - Lee, Min Soo

AU - Sang, Ick Lee

AU - Sang, Yeol Lee

AU - Sun, Woo Lee

AU - Youn, Tak

AU - Bahk, Won Myong

AU - Lee, Yanghyun

AU - Young, Chul Chung

AU - Young, Chul Shin

AU - Young, Hoon Kim

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Aims: To date there have been no reports of long-term efficacy of aripiprazole in Asian populations. The aim of the present study was therefore to investigate the long-term efficacy, safety and tolerability of aripiprazole in a large number of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder in Korea. Methods: This study was a prospective, multicenter, single-group, 26-week open study of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. A total of 300 Korean patients participated in the study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score, and secondary efficacy measures included the PANSS positive and negative subscales, Clinical Global Impression-Severity of Illness (CGI-S). Tolerability and safety were assessed by monitoring the frequency and severity of treatment-emergent adverse events, extrapyramidal symptoms (EPS), vital signs, weight, and laboratory tests. Results: Aripiprazole produced rapid and significant improvements on all efficacy measures. As evidenced by PANSS total score, PANSS positive subscales and the CGI-S scores, first-episode drug-naïve patients demonstrated significantly greater efficacy relative to patients who had previously experienced one or more episodes of relapse. Aripiprazole was associated with significant decrease of serum prolactin level. The subjects showed mild weight gain. Conclusion: Aripiprazole is an effective antipsychotic in the long-term treatment of both positive and negative symptoms. This study extends the findings of previous long-term studies, and has found that there is no significant difference with regard to ethnicity in response to aripiprazole.

AB - Aims: To date there have been no reports of long-term efficacy of aripiprazole in Asian populations. The aim of the present study was therefore to investigate the long-term efficacy, safety and tolerability of aripiprazole in a large number of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder in Korea. Methods: This study was a prospective, multicenter, single-group, 26-week open study of patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. A total of 300 Korean patients participated in the study. The primary efficacy measure was the Positive and Negative Syndrome Scale (PANSS) total score, and secondary efficacy measures included the PANSS positive and negative subscales, Clinical Global Impression-Severity of Illness (CGI-S). Tolerability and safety were assessed by monitoring the frequency and severity of treatment-emergent adverse events, extrapyramidal symptoms (EPS), vital signs, weight, and laboratory tests. Results: Aripiprazole produced rapid and significant improvements on all efficacy measures. As evidenced by PANSS total score, PANSS positive subscales and the CGI-S scores, first-episode drug-naïve patients demonstrated significantly greater efficacy relative to patients who had previously experienced one or more episodes of relapse. Aripiprazole was associated with significant decrease of serum prolactin level. The subjects showed mild weight gain. Conclusion: Aripiprazole is an effective antipsychotic in the long-term treatment of both positive and negative symptoms. This study extends the findings of previous long-term studies, and has found that there is no significant difference with regard to ethnicity in response to aripiprazole.

UR - http://www.scopus.com/inward/record.url?scp=58449126907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449126907&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1819.2008.01907.x

DO - 10.1111/j.1440-1819.2008.01907.x

M3 - Article

VL - 63

SP - 73

EP - 81

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 1

ER -